Get the Stockscreener App
4.27
1.61%
-0.07
After Hours:
4.26
-0.010
-0.23%
Immuneering Corp stock is traded at $4.27, with a volume of 513.09K.
It is down -1.61% in the last 24 hours and down -18.36% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$4.34
Open:
$4.36
24h Volume:
513.09K
Relative Volume:
0.58
Market Cap:
$276.26M
Revenue:
$500
Net Income/Loss:
$-54.44M
P/E Ratio:
-3.6627
EPS:
-1.1658
Net Cash Flow:
$-49.91M
1W Performance:
-4.69%
1M Performance:
-18.36%
6M Performance:
-19.74%
1Y Performance:
-46.63%
1-Day Range:
$4.255
$4.40
1-Week Range:
$4.20
$4.665
52-Week Range:
$3.86
$8.48
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
4.27 | 276.26M | 500 | -54.44M | -49.91M | -1.1658 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Initiated | Leerink Partners | Outperform |
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
IMRX Stock On Track For Worst Day In Nearly 5 Months — What’s Driving The Selloff? - Stocktwits
Immuneering to Present at the ESMO Congress 2026 - The Manila Times
A pancreatic cancer drug combination is in a late-stage study. Its trial plan will be shown in Madrid. - Stock Titan
Immuneering Corporation(NasdaqGM: IMRX) added to S&P Global BMI Index - marketscreener.com
Immuneering Stock Price Forecast. Should You Buy IMRX? - StockInvest.us
Immuneering at H.C. Wainwright conference: pancreatic cancer push By Investing.com - Investing.com Nigeria
Immuneering at H.C. Wainwright conference: pancreatic cancer push - Investing.com
Immuneering at cantor healthcare conference: pancreatic cancer bet gains focus - Investing.com Canada
Immuneering Stock (IMRX) Opinions on Pancreatic Cancer Drug Presentation - Quiver Quantitative
Immuneering to Present Data on Atebimetinib’s Tumor-Reducing and Body Mass-Preserving Effects in Pancreatic Cancer at AACR Conference - Quiver Quantitative
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival - The Manila Times
84% of evaluable pancreatic cancer patients kept or gained weight after three months - Stock Titan
Immuneering to Participate in Upcoming Investor Conferences - Yahoo Finance
H.C. Wainwright reiterates Immuneering stock rating on MEK pathway potential - Investing.com India
Immuneering comments on FDA pancreatic cancer drug approval By Investing.com - Investing.com India
Immuneering Highlights FDA Approval in Second-Line Pancreatic Cancer as Phase 3 MAPKeeper 301 Enrolls First-Line Patients - Quiver Quantitative
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients - barchart.com
FDA approves a new pancreatic cancer treatment as Immuneering tests a first-line option - Stock Titan
Immuneering Corporation (NASDAQ:IMRX) Given Average Recommendation of "Buy" by Analysts - MarketBeat
HC Wainwright Estimates Immuneering Q3 Earnings - MarketBeat
Immuneering Corp (IMRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immuneering (NASDAQ:IMRX) Now Covered by HC Wainwright - MarketBeat
Immuneering (NASDAQ:IMRX) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
H.C. Wainwright initiates Immuneering stock coverage with buy rating - Investing.com
H.C. Wainwright initiates Immuneering stock coverage with buy rating By Investing.com - Investing.com India
HC Wainwright Initiates Immuneering at Buy With $14 Price Target - Yahoo Finance
Immuneering (NASDAQ:IMRX) Releases Earnings Results - MarketBeat
Immuneering Corp 2026: Revenue ($17.44M), Net income ($17.27M), EPS ($0.27) — 10-Q Summary - TradingView
Immuneering Q2 Loss Widens as Cash Runway Extends Into 2029 - Quiver Quantitative
Immuneering reports Q2 2026 net loss $17.3M, cash $182.7M with runway into 2029 - TradingView
Immuneering Reports 17.3-Month Median Overall Survival in First-Line Pancreatic Cancer and Progresses Phase 3 MAPKeeper 301 Trial - quiverquant.com
Immuneering Corporation Q2 Net Income USD -17 - moomoo.com
Immuneering Corp (IMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
IMRX|Immuneering Corp|Price:4.165|Chg%:+0.035 - TradingKey
Immuneering Corp (IMRX) Income Statement - TradingKey
Immuneering Corp (IMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immuneering Corp (IMRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Immuneering Corp (IMRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immuneering Corp (IMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Immuneering Corp (IMRX) Institutional Confidence - TradingKey
IMRX|Immuneering Corp|Price:4.355|Chg%:+0.035 - TradingKey
Immuneering Corp (IMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immuneering Corp (IMRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immuneering Corporation (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Immuneering Corp (IMRX) Cash Flow - TradingKey
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Immuneering Corporation (IMRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Immuneering reports preclinical data on atebimetinib in journal - Investing.com
IMRX Maintains by Needham -- Price Target Raised to $18.00 - GuruFocus
Immuneering Corporation Announces Grants of Inducement Awards - The Manila Times
Form 4 Immuneering Corp For: 17 July By Investing.com - Investing.com Nigeria
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.06%
2.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):